CRISPR Therapeutics에 대한 매도 수량은 투자자에게 CRISPR Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

CRISPR Therapeutics (NASDAQ:CRSP) 주식, 공매도 수량 보고

CRISPR Therapeutics

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

$BTC

ARKK

ARKW

CRSP

DKNG

화요일(11일) 캐시 우드의 아크 인베스트는 템퍼스AI(NASDAQ:TEM), 블록(NYSE:XYZ), 드래프트킹스(NASDAQ:DKNG)과 관련해 주목할

아크 인베스트: 템퍼스AI에 지속 투자, 기술주 급락 후 블록 매도 등

Equities

Mid Cap

News

Movers

Trading Ideas

AXSM

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Biotech

Markets

Tech

ETFs

ACCD

ACHR

ADYEY

ARKG

ARKX

AVAV

RBLX

금요일에 캐시 우드가 이끄는 아크 인베스트가 크리스퍼 테라퓨틱스 AG(NASDAQ:CRSP), 10X 지노믹스(NASDAQ:TXG), 로블록스(NYSE:RBLX), 아처 에비에이션(NYSE:ACHR), 누 홀딩스(NYSE:NU), 아디옌 NV(OTC:ADYEY), 애콜레이드(NASDAQ:ACCD) 그리고 에어로바이런먼트(NASDAQ:AVAV)와 관련된 주요 거래를 했다.

아크 인베스트 크리스퍼 테라퓨틱스 투자로 생명공학에 베팅, 로블록스에서 매도

CRISPR Therapeutics AG

Cantor Fitzgerald analyst Matthew Prisco maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Overweight and lowers the price target from $315 to $300.

Price Target

Analyst Ratings

NVMI

Cantor Fitzgerald Maintains Overweight on Nova, Lowers Price Target to $300

Charles Schwab Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) shares are trading higher on Friday after the company <a href="https://www.benzinga.com/pressreleases/25/03/b44327104/schwab-reports-monthly-activity-highlights" target="_blank" rel="noreferrer noopener">reported activity for February 2025</a>.
The company&#8217;s core net new assets brought to the company by new and existing clients stood at $48.0 billion, up around 44% year-over-year.
As of the end of February, total client assets came in at $10.28 trillion, up 16% from February 2024 and down 1% vs. January 2025.
In the month, new brokerage accounts opened was 362,000, with February daily average trades rising 1% month-over-month to 7.45 million, led by a continued interest in equity securities.
Transactional sweep cash increased by $4.7 billion to end February at $404.3 billion.
Last month, the company reported growth of over 75% Y/Y to $30.6 billion in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43728999/schwab-reports-monthly-activity-highlights" rel="noreferrer noopener">core net new assets in January 2025</a>.
As of the end of January, total client assets totaled $10.33 trillion, up 21% from January 2024.
In January, the company reported fourth-quarter revenue of&nbsp;$5.33 billion, beating the consensus of&nbsp;$5.19 billion, and adjusted EPS increased 49% to $1.01,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/43100176/charles-schwab-delivers-strong-q4-higher-trading-volumes-and-increased-assets-drive-growth" rel="noreferrer noopener">beating the consensus of&nbsp;$0.91</a>.
Investors can gain exposure to the stock via IShares U.S. Broker-Dealers &amp; Securities Exchanges ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAI#NYSE">IAI</a>) and iShares FinTech Active ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPAY#NYSE">BPAY</a>).
SCHW Price Action: Charles Schwab shares are up 5.06% at $77.21 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/02/43661564/charles-schwab-rolls-out-24-5-trading-etf-store-president-says-you-may-not-like-it-but" target="_blank" rel="noreferrer noopener">Charles Schwab Rolls Out 24/5 Trading, ETF Store President Says &#8216;You May Not Like It But&#8230;&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

BlackRock ETF Trust BlackRock Future Financial and Technology ETF

BPAY

iShares Dow Jones US Broker Dealers Index Fund

SCHW

Charles Schwab Stock Rises As February Core Net New Assets Surge 44% Year-Over-Year

Cantor Fitzgerald analyst Andres Sheppard reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Overweight and maintains $5 price target.

Reiteration

EVEX

Cantor Fitzgerald Reiterates Overweight on Eve Holding, Maintains $5 Price Target

Wells Fargo analyst Michael Turrin maintains DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Underweight and raises the price target from $70 to $73.

DOCU

Wells Fargo Maintains Underweight on DocuSign, Raises Price Target to $73

Macro Economic Events

Market Summary

Economics

General

Beninga Market Summary: US Consumer Sentiment Falls, S&P Rebounds Following Recent Losses, Chip Stocks Rise

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterates Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and maintains $85 price target.

RBRK

Cantor Fitzgerald Reiterates Overweight on Rubrik, Maintains $85 Price Target

WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares are trading higher on Friday. Total revenue for the fourth quarter was RMB140.8 million ($19.3 million), down from <a href="https://www.benzinga.com//node/44323329">RMB144.8 million in the same period of 2023.</a>
The company&#8217;s fourth-quarter product revenue jumped to RMB51.7M million ($7.1 million), driven by strong sales of robotaxis, robosweepers, and robovans. Service revenue declined to RMB89.1 million ($12.2 million) due to lower revenue from ADAS research and development services.
Non-IFRS adjusted net loss&nbsp;was RMB245.5 million ($33.6 million), compared to RMB115.7 million in the year-ago quarter.
As of Dec 31, 2024, WeRide held $669.7 million in cash and deposits, plus $238.7 million in financial assets.
WeRide is accelerating its global expansion with key launches across the Middle East, <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43918424/werides-gxr-robotaxi-launches-first-fully-driverless-commercial-service-in-beijing-details" rel="noreferrer noopener">China</a>, and <a target="_blank" href="https://www.benzinga.com/markets/equities/25/02/44041348/werides-robobus-rolls-out-in-france-with-renault-beti-backing-details" rel="noreferrer noopener">Europe</a>. In Abu Dhabi, the company is scaling its robotaxi fleet in partnership with Uber, targeting 50 vehicles by mid-2025 and expanding coverage across major city routes.
In March 2025, WeRide officially secured the permit to conduct commercial robotaxi ride-hailing services between the Beijing Economic-Technological Development Area and Beijing South Railway Station.
In Europe, WeRide entered Switzerland as the tech provider for the country's first autonomous robotaxi pilot project, backed by the Canton of Zurich and Swiss Railways.
Jennifer Li, WeRide's Chief Financial Officer, commented, &#8220;Amidst a challenging macro environment, we adopted a comprehensive approach in 2024 to optimize revenue and customer structure through internationalization, competitive pricing, and strategic partnerships. This strategy delivered meaningful results in 2024, including achieving record-high robotaxi revenue and the strongest growth of international revenue since company's inception.&#8221;
For the full-year, total revenue declined to RMB361.1 million ($49.5 million) from RMB401.8 million in 2023.
Price Action: WRD shares are trading higher by 2.34% to $16.65 at the last check Friday.
Image Source: WeRide Inc.

Earnings

WeRide Stock Rises Despite Q4 Revenue Dip, Product Revenue Jumps

Wells Fargo analyst Andrew Nowinski maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and raises the price target from $76 to $80.

Wells Fargo Maintains Overweight on Rubrik, Raises Price Target to $80

Cantor Fitzgerald analyst Li Watsek initiates coverage on Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) with a Overweight rating.

Initiation

TARA

Cantor Fitzgerald Initiates Coverage On Protara Therapeutics with Overweight Rating

Wells Fargo analyst John Kilichowski maintains FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) with a Overweight and lowers the price target from $20 to $19.

Wells Fargo Maintains Overweight on FrontView REIT, Lowers Price Target to $19

U.S. stocks were higher, with the Dow Jones index gaining around 1% on Friday.
Shares of Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/25/03/44317455/semtech-shares-soar-after-better-than-expected-q4-results-details">fourth-quarter financial results</a>.
Semtech reported quarterly earnings of 40 cents per share, which beat the analyst consensus estimate of 32 cents by 25%. Quarterly revenue of $251 million beat the consensus estimate of $249.19 million and is up from $192.94 million from the same period last year.
Semtech shares jumped 12.7% to $36.86 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Radius Recycling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>) shares jumped 103% to $27.66 after the company disclosed a merger deal with Toyota Tsusho America, Inc. for $30.00 per share in cash.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 37.7% to $21.86 after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares climbed 26% to $8.73 on continued strength after the company on Thursday reported a 502% year-over-year increase in fourth-quarter bookings to $18.3 million.</li>
<li>Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) shares rose 25% to $69.08 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) gained 24% to $2.0950. HC Wainwright &amp; Co. analyst Ed Arce reiterated Akebia Therapeutics with a Buy and maintained a $7.5 price target.</li>
<li>Green Dot Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) rose 20.9% to $8.03.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) gained 17.5% to $7.70 following fourth-quarter earnings.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) jumped 17% to $10.22.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) rose 15% to $85.78 following better-than-expected quarterly financial results.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) jumped 15% to $10.43.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) surged 15% to $2.61 following FY 2024 results.</li>
<li>Afya Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) gained 13.3% to $18.38 following upbeat earnings.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) rose 12.7% to $17.59 after the company reported better-than-expected quarterly financial results and issued FY26 adjusted EPS guidance above estimates.</li>
<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) rose 12.5% to $120.97 after the company reported better-than-expected quarterly financial results.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) gained 10.6% to $9.85.</li>
<li>Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) surged 8.5% to $101.50 following upbeat quarterly sales.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) rose 6.8% to $101.32.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) gained 6.7% to $335.48 after the company reported better-than-expected quarterly financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 6.2% to $177.02. B of A Securities analyst Michael McGovern maintained Carvana with a Buy and lowered the price target from $270 to $220.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

AAOI

AFYA

AKBA

BTBT

CVNA

FUTU

GDOT

QBTS

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday

Econ #s

CORRECTION: Michigan Consumer Sentiment (Mar) 57.9

Macro Notification

Michigan Consumer Sentiment (Mar) 57.9 vs 63.1 Est.; Prior 64.7

Throughout the last three months, 4 analysts have evaluated Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.5, a high estimate of $56.00, and a low estimate of $41.00. Observing a downward trend, the current average is 7.63% lower than the prior average price target of $54.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960868_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Six Flags Entertainment among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Curry Baker</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Six Flags Entertainment. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Six Flags Entertainment compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Six Flags Entertainment's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Six Flags Entertainment's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Six Flags Entertainment analyst ratings.</a>
<h2>Discovering Six Flags Entertainment: A Closer Look</h2>
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
<h3>Financial Milestones: Six Flags Entertainment's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Six Flags Entertainment showcased positive performance, achieving a revenue growth rate of 85.2% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Six Flags Entertainment's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -38.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Six Flags Entertainment's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -12.06%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Six Flags Entertainment's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.86%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Six Flags Entertainment's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.53.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Six Flags Entertainment Through The Eyes Of 4 Analysts

Wells Fargo analyst Colin Langan maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Underweight and lowers the price target from $135 to $130.

TSLA

Wells Fargo Maintains Underweight on Tesla, Lowers Price Target to $130

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ANI Pharmaceuticals, presenting an average target of $86.25, a high estimate of $94.00, and a low estimate of $80.00. This current average represents a 3.09% decrease from the previous average price target of $89.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960857_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of ANI Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Ekaterina Knyazkova</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ANI Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ANI Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ANI Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into ANI Pharmaceuticals's Background</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ANI Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 44.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -5.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ANI Pharmaceuticals's ROE excels beyond industry benchmarks, reaching -2.64%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.83%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.55, ANI Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $7.38, a high estimate of $8.00, and a low estimate of $7.00. Experiencing a 4.03% decline, the current average is now lower than the previous average price target of $7.69. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960845_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of National CineMedia by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Patrick Sholl</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>James Goss</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$8.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National CineMedia. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of National CineMedia compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for National CineMedia's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into National CineMedia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NCMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on National CineMedia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About National CineMedia</h2>
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
<h3>National CineMedia's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: National CineMedia's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -4.96%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: National CineMedia's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.62%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): National CineMedia's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): National CineMedia's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: National CineMedia's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NCMI

Breaking Down National CineMedia: 4 Analysts Share Their Views

Fox News' usually friendly coverage of President Donald Trump took a sharp turn when White House correspondent Peter Doocy pressed the administration on economic concerns not once but three times in a single day.
<h2 class="wp-block-heading">Market Drop Raises Questions</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Peter Doocy zinged President Donald Trump over the cratering stock market with a brutal wisecrack to Trump White House Press Secretary Karoline Leavitt. <a href="https://t.co/aPS6bumNBn">pic.twitter.com/aPS6bumNBn</a>
&mdash; Mediaite (@Mediaite) <a href="https://twitter.com/Mediaite/status/1899596304851865955?ref_src=twsrc%5Etfw">March 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
During a White House press briefing on March 11, Doocy put press secretary Karoline Leavitt on the spot about the market downturn. He asked, "So you said that <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44258002/wall-street-drop-deepens-as-trade-war-fears-escalate-sp-500-hits-7-month-lows-whats-driving-markets-tuesday">the Dow dropping</a> and dropping and dropping is a period of transition. You're sure nobody here at the White House shorted the Dow?" he asked.
"No, I don't think so," Leavitt replied.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Doocy then pressed her again about the administration&#8217;s plan to encourage federal workers to retire amid stock market losses.
"Is there any concern here that it's gonna be harder to ask certain federal workers to retire if they look at their retirement accounts and they're getting dropped every day?"
Leavitt sidestepped the question, instead pivoting to Trump's broader economic strategy.
"I'm glad you brought up workers because that's exactly who President Trump is looking out for with his America First trade policy and his America First economic agenda," she said, emphasizing fair trade practices and worker protections.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Doocy Presses Trump Directly</h2>
Later that day, Doocy took his concerns straight to the president. During an event outside the White House, where <a href="https://www.benzinga.com/markets/25/03/44240714/trump-says-he-will-buy-a-brand-new-tesla-to-support-elon-musk-as-stock-falls-over-53-erasing-nearly-800-billion-in-investor-wealth-since-december-peak">Trump was promoting Tesla</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and announcing that he planned to buy one of the company's vehicles at full price, Doocy challenged him on the optics of making such a purchase while Americans were struggling financially.
"What is your message, President Trump, buying a new car while there are some folks who will see this clip at home and they are struggling with their retirement accounts, down at the moment, uncertainty about work?" Doocy <a href="https://www.youtube.com/live/TkZdFtvAkGs?si=EviGlFmau5fOTaIr&amp;t=2529">asked</a>.
See Also: <a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a>
Trump largely avoided the economic question, instead using the opportunity to tout his economic record and criticize past administrations for outsourcing U.S. manufacturing jobs.
"I think they&#8217;re going to do great," Trump said. "Our country had to do this. We had to go and do this. Other countries have taken away our business. They've taken away our jobs."
Trump defended his first term as "the greatest economy in the history of our country" before the COVID-19 pandemic and predicted that the current economy would surpass it. He also stressed the importance of bringing back jobs and reopening factories, blaming previous presidents for the loss of U.S. manufacturing.
While Fox News is typically a reliable ally for Trump, Doocy's line of questioning suggests that even <a href="https://www.benzinga.com/news/25/02/43532051/fox-news-stuns-audience-with-a-scrolling-list-of-goods-facing-tariffs-virtually-every-sector-of-the-american-economy-potentially-targeted">conservative media is taking notice</a> of the administration's economic challenges.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

'You're Sure Nobody In The White House Shorted The Dow?'—Fox's Peter Doocy Challenges Trump Three Times In A Day

In the latest quarter, 4 analysts provided ratings for DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $99.25, a high estimate of $124.00, and a low estimate of $75.00. Experiencing a 2.22% decline, the current average is now lower than the previous average price target of $101.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960836_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of DocuSign by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DocuSign. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DocuSign compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for DocuSign's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into DocuSign's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DocuSign analyst ratings.</a>
<h2>About DocuSign</h2>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in May 2018.
<h3>DocuSign's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, DocuSign showcased positive performance, achieving a revenue growth rate of 7.77% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: DocuSign's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): DocuSign's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.16%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): DocuSign's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.66%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, DocuSign adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DocuSign Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

eBay's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NYSE">EBAY</a>) short percent of float has fallen 6.49% since its last report. The company recently reported that it has 17.56 million shares sold short, which is 4.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>eBay Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741960829_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for eBay has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing eBay's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, eBay's peer group average for short interest as a percentage of float is 11.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

EBAY

What Does the Market Think About eBay?

Press Releases

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Health Care

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Management

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Comments

CRISPR Therapeutics

매도 수량

CRISPR Therapeutics (NASDAQ:CRSP) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌